#CRNX↓

Crinetics Acromegaly Drug Approval Drives Stock Surge

Crinetics' stock surged after the FDA approved Palsonify, their once-daily oral drug for acromegaly. This rare disorder results in too much growth hormone. Palsonify is the first oral option, offering rapid, consistent control and reduced symptoms. It will be available in early October.